相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Immune checkpoint blockade immunotherapy to activate anti-tumour T-cell immunity
Alan G. Ramsay
BRITISH JOURNAL OF HAEMATOLOGY (2013)
Targeting the Immune System in the Treatment of Non-Small-Cell Lung Cancer
Deepa Rangachari et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2013)
Anti-PD-1 Blockade and Stereotactic Radiation Produce Long-Term Survival in Mice With Intracranial Gliomas
Jing Zeng et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2013)
At the Bedside: CTLA-4-and PD-1-blocking antibodies in cancer immunotherapy
Margaret K. Callahan et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2013)
Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma
Omid Hamid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Nivolumab plus Ipilimumab in Advanced Melanoma
Jedd D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
PD-1 Blockade Enhances T-cell Migration to Tumors by Elevating IFN-γ Inducible Chemokines
Weiyi Peng et al.
CANCER RESEARCH (2012)
Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity
Suzanne L. Topalian et al.
CURRENT OPINION IN IMMUNOLOGY (2012)
Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Dual biological effects of the cytokines interleukin-10 and interferon-γ
Cailin Moira Wilke et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2011)
Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion
Robert D. Schreiber et al.
SCIENCE (2011)
Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
Julie R. Brahmer et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired
Mojgan Ahmadzadeh et al.
BLOOD (2009)
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
Jedd D. Wolchok et al.
CLINICAL CANCER RESEARCH (2009)
Anti-Programmed Death-1 Synergizes with Granulocyte Macrophage Colony-Stimulating Factor-Secreting Tumor Cell Immunotherapy Providing Therapeutic Benefit to Mice with Established Tumors
Betty Li et al.
CLINICAL CANCER RESEARCH (2009)
Human Prostate-Infiltrating CD8+ T Lymphocytes are Oligoclonal and PD-I+
Karen S. Sfanos et al.
PROSTATE (2009)
Programmed death 1 is a marker of angioimmunoblastic T-Cell lymphoma and B-cell small lymphocytic lymphoma/chronic lymphocytic leukemia
Luc Xerri et al.
HUMAN PATHOLOGY (2008)
Inhibitory B7-family molecules in the tumour microenvironment
Weiping Zou et al.
NATURE REVIEWS IMMUNOLOGY (2008)
Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-γ and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway
Jizhong Liu et al.
BLOOD (2007)
Programmed death-1 (PD-1) is a marker of germinal center-associated T cells and angioimmunoblastic T-cell lymphoma
DM Dorfman et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2006)
Interferon regulatory factor-1 is prerequisite to the constitutive expression and IFN-γ-induced upregulation of B7-H1 (CD274)
SJ Lee et al.
FEBS LETTERS (2006)
Costimulatory molecule B7-H1 on primary and metastatic clear cell renal cell carcinoma
RH Thompson et al.
CANCER (2005)
B7-H1 glycoprotein blockade: A novel strategy to enhance immunotherapy in patients with renal cell carcinoma
RH Thompson et al.
UROLOGY (2005)
Expression of functional B7-H2 and B7.2 costimulatory molecules and their prognostic implications in de novo acute myeloid leukemia
H Tamura et al.
CLINICAL CANCER RESEARCH (2005)
In vivo costimulatory role of B7-DC in tuning T helper cell 1 and cytotoxic T lymphocyte responses
T Shin et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target
RH Thompson et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Interferon-β enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation:: relevance for the immune modulatory effect in multiple sclerosis
B Schreiner et al.
JOURNAL OF NEUROIMMUNOLOGY (2004)
Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma
A Rosenwald et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2003)
Expression of programmed death 1 ligands by murine T cells and APC
T Yamazaki et al.
JOURNAL OF IMMUNOLOGY (2002)
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade
Y Iwai et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation
GJ Freeman et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens
FV Fossella et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy
FA Shepherd et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
分享论文
